BS Summary: This article contains 17 faulty reasoning types, including Biased Writer Voice, Anchoring Bias, and Optimism Bias, with Attempt to Sell a Product or Service as the most egregious example at 35.5% saturation with 127 hits. Analysis detected 435 faulty-reasoning hits from 358 analyzed words, generating a BS Score of 48% and a BS Rank of 46% (11,935 of 21,886 articles). This article is better (less manipulative) than 54.50% of the article peer group.
Tau in the spotlight at Alzheimer’s conference
You’re reading STAT’s AAIC in 30 newsletter
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent.
You can reach Andrew confidentially on Signal at drewqjoseph.71.
This is the web edition of STAT’s AAIC in 30 newsletter.
Sign up to get it in your inbox here .
Welcome to the first edition of our pop-up newsletter from AAIC .
I’m STAT’s London-based reporter, and I’ll be here with you over the next couple days.
I hope those of you in town can find time to escape the abyss of the conference center and enjoy London, because this city in the summer is something special.
Maybe you’re ahead of the curve and took in England’s win last night.
In which case, maybe you’re joining me in needing to pound the coffee.
Any thoughts, questions, or hot takes on Zverev v.
Sinner, I’m at [email protected] .
One other note before we get going: STAT has put together a special report on dementia diagnostics, treatments, and care.
We also have a special conference discount on offer, so head here and use the code “AAIC” to download the report for only $5.
With the exchange rate, that’s less than the cost of this morning’s flat white.
STAT+ Exclusive Story
Already have an account?
Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Totals $468 per year
for 3 months, then $399/year
Savings start at 25%!
$300 Annually per user
To read the rest of this story subscribe to STAT+.
Alzheimer’s , biotechnology , drug development , Pharmaceuticals , Policy , research , STAT+
Submit a correction request Reprints
STAT Plus: Roche ends Huntington’s gene-silencing programs
STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs
STAT Plus: Prime wins Beam arbitration, clearing path to clinic
Adam's Biotech Scorecard
STAT Plus: 931 days.
The drug approval scandal hiding in plain sight
STAT Plus: AstraZeneca, Ionis report major trial failure with heart disease drug
Speakers
4speakers40%attributed speech215writer words
Voice mapSelect a segment to jump to its words
Selected voice
92%flagged-word coverageSTAT
37 attributed words26% of attributed speech66% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.